HPV genoprevalence and HPV knowledge in young women in Mongolia, five years following a pilot 4vHPV vaccination campaign
Tsetsegsaikhan Batmunkh, Claire von Mollendorf, Khosbayar Tulgaa, Unursaikhan Surenjav, Marguerite T Dalmau, Narantuya Namjil, Battsetseg Tsedevdamba, Sambuu Tsegmed, Jalserd Enkhmaa, Suzanne M Garland, Kim Mulholland
PAPILLOMAVIRUS RESEARCH | ELSEVIER | Published : 2019
BACKGROUND: In a 2012 pilot, 9111 Mongolian girls aged 11-17 years received three doses of the quadrivalent (4vHPV) vaccine, Gardasil®. This is the first study to measure early vaccine effectiveness and assess knowledge and attitudes of young women in Mongolia in relation to the human papillomavirus (HPV), the vaccine and cervical cancer. METHODS: A cohort of women vaccinated in 2012 (n = 726) and an unvaccinated cohort (n = 790) provided self-administered vaginal swabs for detection of high-risk HPV genotypes 16, 18/45, 31, 33, 35, 39, 51, 52, 56, 58, 59, 66, 68 five years following vaccination. Participant knowledge and attitudes were assessed through a questionnaire. RESULTS: A total of 1..View full abstract
Awarded by Australian Department of Foreign Affairs and Trade Direct Aid Program
Awarded by World Health Organization, Mongolia office
Co-funding was provided by the Australian Department of Foreign Affairs and Trade Direct Aid Program (Grant ID: ULNB/2016-2017/003), the Murdoch Children's Research Institute and the World Health Organization, Mongolia office (Grant ID: 201594897, WPMNG1611473). The Australian Department of Foreign Affairs and Trade and the World Health Organization had no involvement in the study process. Researchers at the Murdoch Children's Research Institute provided support on study design, data analysis and interpretation.